Latest news
Inetetamab-Pyrotinib Regimen Shows High pCR in HER2-Positive Breast Cancer - Targeted OncologyTargeted Oncology · Sat, 08 Aug 2026 15:11:40 GMTHER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 13:47:28 GMTDual Checkpoint Blockade Boosts Breast Cancer pCR - MedscapeMedscape · Wed, 05 Aug 2026 12:19:22 GMTNeoadjuvant iSBRT Plus Durvalumab Boosts pCR in Cold Breast Tumors - Targeted OncologyTargeted Oncology · Tue, 04 Aug 2026 13:13:58 GMTPathologic Complete Response Following Frailty-Adjusted Neoadjuvant Paclitaxel in an 88-Year-Old Patient With Radiation-Associated Breast Angiosarcoma - CureusCureus · Fri, 31 Jul 2026 20:31:25 GMT